Sentiment-Signal
Score-Verlauf (90 Tage)
Stammdaten
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.
Unternehmen & Branche
| Name | Immix Biopharma, Inc. |
|---|---|
| Ticker | IMMX |
| CIK | 0001873835 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 455,8 Mio. USD |
| Beta | 0,21 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -29,438,613 | -0.89 | 104,840,341 | ||
| 2025-09-30 | 10-Q | -7,585,692 | -0.24 | 20,080,604 | ||
| 2025-06-30 | 10-Q | -6,622,563 | -0.22 | 15,635,104 | ||
| 2025-03-31 | 10-Q | -4,542,528 | -0.15 | 19,892,040 | ||
| 2024-12-31 | 10-K | -21,613,376 | -0.76 | 22,947,872 | 13,251,203 | |
| 2024-09-30 | 10-Q | -7,149,395 | -0.24 | 25,141,552 | 17,550,711 | |
| 2024-06-30 | 10-Q | -4,392,936 | -0.15 | 28,835,944 | 23,891,221 | |
| 2024-03-31 | 10-Q | -5,258,991 | -0.22 | 34,347,592 | 27,915,145 | |
| 2023-12-31 | 10-K | -15,426,048 | -0.89 | 19,925,160 | 16,405,114 | |
| 2023-09-30 | 10-Q | -4,280,664 | -0.23 | 22,474,778 | 19,773,941 | |
| 2023-06-30 | 10-Q | -3,576,216 | -0.24 | 15,566,487 | 13,227,343 | |
| 2023-03-31 | 10-Q | -2,479,664 | -0.18 | 13,211,467 | 11,770,899 | |
| 2022-12-31 | 10-K | -8,229,713 | -0.59 | 14,908,101 | 13,159,805 | |
| 2022-12-08 | 10-Q | 20,000,000 | ||||
| 2022-12-08 | 10-K | 20,000,000 | ||||
| 2022-09-30 | 10-Q | -1,535,050 | -0.11 | 17,395,039 | 16,748,582 | |
| 2022-06-30 | 10-Q | -1,562,778 | -0.11 | 19,088,038 | 18,110,829 | |
| 2022-03-31 | 10-Q | -1,332,048 | 20,017,498 | 19,652,412 | ||
| 2021-12-31 | 10-K | -24,383,879 | 18,192,088 | 17,990,049 | ||
| 2021-09-30 | 10-Q | -403,265 | -6,195,699 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.